What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?

Ming-Yow Hung, Sotirios Tsimikas

研究成果: 雜誌貢獻文章同行評審

20 引文 斯高帕斯(Scopus)

摘要

Purpose of review: Lipoprotein(a) [Lp(a)] is a risk factor for cardiovascular disease (CVD) and calcific aortic valve stenosis. We review recent studies that highlight Lp(a) in CVD and calcific aortic valve stenosis and propose pathways to clinical registration of Lp(a)-lowering agents. Recent findings: Over the last few years, almost irrefutable evidence has accumulated that Lp(a) is a causal, independent, genetic risk factor for CVD. Most recently, new data have emerged that elevated Lp(a) is causally associated with calcific aortic valve stenosis and the need for aortic valve replacement. Three levels of evidence to support these findings: epidemiological studies, Mendelian randomization studies and genetic association studies. A dedicated Lp(a)-lowering trial has not been performed to date. Emerging Lp(a)-lowering therapies with specific and potent lowering of Lp(a) are in phase II clinical trials and provide a tool to test the hypothesis that lowering Lp(a) plasma levels will lead to clinical benefit. Summary: We provide a rationale for the potential clinical use of Lp(a)-lowering therapies in high-risk patients or patients with established CVD whose major risk factor is elevated Lp(a) levels and propose clinical studies and trials to demonstrate that lowering Lp(a) levels will effectively reduce the risk of calcific aortic valve stenosis and CVD.
原文英語
頁(從 - 到)423-430
頁數8
期刊Current Opinion in Lipidology
25
發行號6
DOIs
出版狀態已發佈 - 2014

ASJC Scopus subject areas

  • 細胞生物學
  • 遺傳學
  • 分子生物學
  • 心臟病學與心血管醫學
  • 內分泌學、糖尿病和代謝
  • 營養與營養學
  • 醫藥 (全部)

指紋

深入研究「What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?」主題。共同形成了獨特的指紋。

引用此